Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

vasopharm GMBH

www.vasopharm.com

Latest From vasopharm GMBH

Cellvation Tackling Traumatic Brain Injuries With Stem Cell Therapy

Emerging Company Profile: With mononuclear stem cell therapy from University of Texas research, new company hopes to address traumatic brain injury by reducing the pro-inflammatory cytokine cascade, which exacerbates the initial injuries in severe TBI.

Regenerative Medicine Business Strategies

PIPELINE WATCH: Three Approvals, Five Filings And Two Launches

This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.

Pipeline Watch Approvals

Venture Funding Deals, February 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research, Analytical Equipment and Supplies sectors. This month’s column covers deals announced December 2015 through January 2016.

BioPharmaceutical Medical Device

Biopharma Dealmaking Quarterly Statistics, Q2 2013

Q2 2013 biopharma financing increased 139% to $11 billion over Q1’s $4.6 billion, thanks mostly to two huge transactions by Valeant to fund its $8.7 billion takeover of ophthalmics player Bausch & Lomb, the company’s largest acquisition to date. Options and antibody-drug conjugates featured prominently in the alliances.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • vasopharm Biotech GMBH
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • vasopharm GMBH
  • Senior Management
  • Christian Wandersee, CEO
    Frank Tegtmeier, PhD, CSO
  • Contact Info
  • vasopharm GMBH
    Phone: (49) 931 35 90 99-0
    Friedrich-Bergius-Ring 15
    Wuerzburg, 97076
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register